An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: Subgroup analysis of the BENIFICIARY study

American Journal of Cardiovascular Drugs

Volumn 10, Issue 5, 2010, Pages 289-303

  Neutel, Joel M ^a   Kereiakes, Dean J ^b  

^a Orange County Research Center   (United States)

^b The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

Age differences; Ethnic groups; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil; Olmesartan medoxomilhydrochlorothiazide; Sex differences; Type 2 diabetes mellitus

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO;

ADULT; AGE; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; EDEMA; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RACE; SEX; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; TETRAZOLES;

EID: 77957297381     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11584690-000000000-00000     Document Type: Article

References (28)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008 Jan 29; 117 (4): e25-146 (Pubitemid 43754289)
2. Kabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr 2006 Spring; 1(2):95-101
3. Resnick HE, Foster GL, Bardsley J, et al. Achievement of American Diabetes Association clinical practice recommendations among U. S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006 Mar; 29(3):531-7 (Pubitemid 44115349)
4. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002 Jan; 25(1):134-47 (Pubitemid 41185048)
5. Legato MJ, Gelzer A, Goland R, et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006 Jun; 3(2):131-58 (Pubitemid 44069479)
6. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008 Jan; 31 Suppl. 1: S12-54
7. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6):1206-52 (Pubitemid 37553153)
8. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 Jun; 25(6):1105-87 (Pubitemid 46924065)
9. Rodbard H, Blonde L, Braithwaite S, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 May-Jun; 13 Suppl. 1:1-68
10. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007 Jan; 49(1):69-75 (Pubitemid 46360343)
11. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002 Apr; 25(4):718-23 (Pubitemid 41071193)
12. Pessina AC. Target organs of individuals with diabetes caught between arterial stiffness and damage to the microcirculation. J Hypertens 2007 Jun; 25 Suppl. 1: S13-8
13. Neutel JM, Kereiakes DJ, Waverczak WF, et al. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Curr Med Res Opin 2010 Mar; 26(3):721-8
14. Jula A, Puukka P, Karanko H. Multiple clinic and home blood pressure measurements versus ambulatory blood pressure monitoring. Hypertension 1999 Aug; 34(2):261-6 (Pubitemid 29409225)
15. Mancia G, Parati G. Ambulatory blood pressure monitoring and organ damage. Hypertension 2000 Nov; 36(5):894-900
16. Mancia G, Parati G, Hennig M, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001 Nov; 19(11):1981-9 (Pubitemid 33035803)
17. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure inpredicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997 Mar. 18;95(6):1464-70 (Pubitemid 27329663)
18. Neutel JM. The importance of 24-h blood pressure control. Blood Press Monit 2001 Feb; 6(1):9-16 (Pubitemid 32269925)
19. Fliser D, Wagner KK, Loos A, et al. Chronic angiotensin II receptor blockade reduces (intra) renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005 Apr; 16(4):1135-40 (Pubitemid 41710325)
20. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese earlystage type-2 diabetics with hypertension. Hypertens Res 2008 Jan; 31(1):7-13 (Pubitemid 351325609)
21. Fukuda M, Yamanaka T, Mizuno M, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008 Mar; 26(3):583-8 (Pubitemid 351317269)
22. Kereiakes DJ, Neutel J, Stoakes KA, et al. The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in patients aged 65 and older. J Clin Hypertens (Greenwich) 2009;11:1-11
23. Chavanu K, Merkel J, Quan AM. Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 2008 Feb. 1;65(3):209-18 (Pubitemid 351220770)
24. Manios ED, Koroboki EA, Tsivgoulis GK, et al. Factors influencing whitecoat effect. Am J Hypertens 2008 Feb; 21(2):153-8
25. Palatini P. Too much of a good thing? A critique of overemphasis on the use of ambulatory blood pressure monitoring in clinical practice. J Hypertens 2002 Oct; 20(10):1917-23 (Pubitemid 35305481)
26. Sega R, Cesana G, Milesi C, et al. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997 Jul; 30 (1 Pt 1):1-6 (Pubitemid 27306339)
27. Calvo C, Hermida RC, Ayala DE, et al. The 'ABPM effect' gradually decreases but does not disappear in successive sessions of ambulatory monitoring. J Hypertens 2003 Dec; 21(12):2265-73 (Pubitemid 38293565)
28. Pang TC, Brown MA. Accuracy of ambulatory blood pressure monitors in routine clinical practice. Am J Hypertens 2006 Aug; 19(8):801-9 (Pubitemid 44107690)